A randomized phase IItrial of mapatumumab, a TRAIL R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC

Aims: Mapatumumab, a fully human agonist mab, targets and activates the death receptor TRAIL-R1. We conducted a randomized, controlled phase II trial to evaluate mapatumumab in combination with carboplatin and paclitaxel as first-line therapy in advanced non-small call lung cancer (NSCLC). Methods: Patients were required to have histol. or cytol. confirmed Stage IIIB or IV advanced primary NSCLC with measurable disease by RECIST. Patients were randomly assigned to Arm A, paclitaxel 200mg/m2 + carboplatin AUC 6.0 (PC);Arm B, PC + mapatumumab 10mg/kg; or Arm C, PC + mapatumumab 30mg/kg. Cycles were repeated every…